PolyPid Ltd. (PYPD)
PolyPid develops drug candidates that release medicine slowly at the treatment site, led by D-PLEX100 for preventing surgical site infections. It last closed at $6.54 on Nov 17, up 6.34% on the day. PYPD reports earnings on Wed, Feb 10, 2027.
Key Stats
Last 12 monthsNot reported for this period.
From PYPD's SEC filings, latest 20-F for the period ending Dec 31, 2025 (filed Feb 25). Last 12 months adds up the four latest quarters. Per share figures are left out because the US listing can represent a different number of shares.
Earnings
Full earnings history →Analyst Ratings & Price Targets
Analyst Ratings →Based on 1 analyst who set a price target on PYPD in the past 90 days. The average target is $10.00, with a high of $10.00 and a low of $10.00, compared with the last close of $6.54.
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| Oct 27 | Oppenheimer | Initiated | Buy | $10 |
| Jul 21 | HC Wainwright & Co. | Reiterated | Buy | $13 |
Technical Analysis
The stock is 11% above its 20 day and 17% above its 50 day average. It is 26% above its 200 day average, so the longer trend is still up. Momentum is strong (RSI 67), near overbought. The nearest support is the Pivot at $6.42, and the nearest resistance the Pivot R1 at $6.66.
| RSI (14) | 66.69 | Strong, overbought above 70 | Neutral |
| MACD | 0.33 | Above its signal line | Bullish |
| Stochastic | 56.9 | Middle of its range | Neutral |
| ADX (14) | 24.4 | Weak trend | |
| Williams %R | -31.0 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 102.0 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +19.8% | Change over 10 sessions | Bullish |
| ATR (14) | $0.39 | Typical daily range, 5.9% of price |
| RSI (14) | 69.86 | Strong, overbought above 70 | Neutral |
| MACD | 0.39 | Above its signal line | Bullish |
| Stochastic | 81.6 | Near the top of its range | Overbought |
| ADX (14) | 26.2 | Trending up | |
| Williams %R | -22.2 | Oversold below −80, overbought above −20 | Neutral |
| CCI (20) | 202.9 | Oversold below −100, overbought above 100 | Overbought |
| Rate of change | +27.0% | Change over 10 sessions | Bullish |
| ATR (14) | $0.61 | Typical daily range, 9.4% of price |
What happened before
See how PYPD did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record.
Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.
Seasonality
How PYPD has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2020.
Whale Options Flow
90DNo whale options trades in PYPD in the last 90 days.
PYPD Institutional Ownership
Full report →- ▼11 buying vs 16 selling
- ▼Shares held by funds -21.9%
- ▼Funds holding -8
- ▲Superinvestors: 2 added, 0 cut
- ●Put/call not meaningful
| Q3 2026 | This quarter | Last quarter | Change |
|---|---|---|---|
| Funds holding | 25 | 33 | −24.2% |
| In funds' top 10 | 0 | 1 | −100.0% |
| Held by funds | – | – | – |
| New / increased | 2 / 9 | 14 / 5 | −42.1% |
| Reduced / sold out | 6 / 10 | 6 / 0 | +166.7% |
| Put/call ratio | – | – | – |
From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.
AI Auto Pilots
Paper tradingStreetAlpha runs four autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether PYPD is in one of them and how their past PYPD trades turned out.
Macro & Market News
All StreetAlpha news →StreetAlpha hasn't covered PYPD in an article yet. Here's the latest on the wider market.
About PolyPid
PolyPid is a biopharmaceutical company based in Petach Tikva, Israel. It develops medicines that release drugs slowly and locally at the site of treatment. Its lead product candidate, D-PLEX100, combines its PLEX technology with the antibiotic doxycycline and is placed directly into the surgical site during surgery to help prevent surgical site infections. The company is also developing treatments for metabolic diseases and cancer, and it plans to license its PLEX technology to other drug developers. Its intended users are surgical patients and the hospitals that treat them.
- Headquarters
- Petach Tikva, Israel

